Realization of Total Supply Chain Services

「This will enable us to evolve and expand our group’s development-to-manufacturing functions within TSCS and further strengthen our system for delivering pharmaceuticals in a wide range of modalities to the medical institutions and patients who need them, based on “Safety,” “Security” and “Integrity.”」

「In September 2025, as part of the "strengthening of the nationwide network" in the medical device field, ティーエスアルフレッサ株式会社 acquired all shares of 株式会社ミヤノメディックス, a specialist medical device trading company headquartered in Fukuyama, Hiroshima Prefecture, making it a subsidiary. 東北アルフレッサ株式会社 also entered into a share transfer agreement to acquire all shares of 東日本メディカルシステム株式会社, a specialist medical device trading company headquartered in Aoba Ward, Sendai (acquisition completed on 31 October). The company aims to further contribute to community healthcare by strengthening the distribution function for medical products within TSCS.」

「Across the Group, we aim to provide seamless services covering the introduction and development of pharmaceuticals and other products, manufacturing, logistics and sales, post-marketing surveillance, and last-mile delivery, while acquiring products subject to restricted distribution, expanding our CDMO business and operating a stable supply chain.」

「We believe that the CRO and PMS business acquired recently can be expected to expand based on the strong relationships of trust that our Group has developed with customers, including medical institutions and pharmaceutical companies, and that the resources and expertise related to CRO and PMS will make a significant contribution to strengthening the Group's clinical development, regulatory filing and PMS functions within its total supply chain.」

「Construction of the new manufacturing building will increase the production capacity for small-molecule pharmaceuticals, enable the Group to make a full-scale entry into contract manufacturing of highly potent drug products and contract testing, inspection and packaging of sterile products, and strengthen and expand the functions spanning development through manufacturing within the Group’s total supply chain services.」

「Cell Resources Co., Ltd., which became a wholly owned subsidiary of the Company through an organizational reorganization, entered into a bioindustry support agreement with Miltenyi Biotec B.V. & Co. KG (head office: Federal Republic of Germany) in July 2023 to support the design, construction and operation of automated cell manufacturing facilities and processes in the gene and cell therapy market. Taking this agreement as an opportunity, the Group is developing the business infrastructure needed to provide highly automated contract cell manufacturing services to the gene and cell therapy market and is establishing a system for providing contract manufacturing services for regenerative medicine and other products.」

「In an organizational reform effective 1 April 2023, we reorganized the organization by establishing, among other units, the Group Medical Wholesale Business Headquarters, the Total Supply Chain Service Planning and Promotion Department, the Regenerative Medicine Business Planning and Development Office, and the Distribution Compliance Office. As an integrated group, we are working to strengthen the business model, create new value and reinforce our compliance framework.」

「In the pharmaceutical and other manufacturing business, the Group is pursuing the following priority initiatives under the 22-24 Medium-Term Plan, with the aim of “Building the foundation for the next generation—Maximizing corporate value”: “Safe, secure and reliable manufacturing,” “Initiatives to realize total supply chain services,” and “New initiatives leveraging digital technology.”」

「Initiatives toward delivering total supply chain services」